Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $74

Benzinga Newsdesk www.benzinga.com Negative 95.1%

Neg 95.1% Neu 0% Pos 0%

Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $87 to $74.